Is Hepatitis B Immunoglobulin Necessary in Prophylaxis of Hepatitis B Recurrence after Liver Transplantation? A Meta-Analysis

Peijie Wang¹²³, Ngalei Tam¹³⁹, Haochen Wang¹³, Huanwei Zheng⁴⁵, Philip Chen⁶, Linwei Wu¹, Xiaoshun He¹

¹ Organ Transplant Center, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, ² Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China, ³ Hepatobiliary Surgery Department, the University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China, ⁴ Liver Disease Department, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, China, ⁵ Clinical Center for Liver Disease, University of Texas, Southwestern Medical Center, Dallas, Texas, United States of America, ⁶ Nephrology Department, University of Texas, Southwestern Medical Center, Dallas, Texas, United States of America

Abstract

Background & Aims: Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B virus (HBV) recurrence rate after liver transplantation (LT) dramatically. Recent data suggests therapy without HBIG is also effective. We sought to evaluate the necessity of HBIG in prophylaxis of HBV recurrence after LT.

Methods: A meta-analysis was performed. PubMed/MEDLINE, Web of Knowledge and other databases were searched for eligible literatures. The major end points were recurrence rate, patient survival, and YMDD mutant. Risk difference (RD) or risk ratio (RR) was calculated to synthesize the results.

Results: Nineteen studies with a total of 1484 patients were included in this analysis. Application of HBIG was helpful to reduce HBV recurrence [P<0.001; RD = 0.16; 95% confidence interval (CI)(0.12, 0.20)] and virus mutants [P<0.001; RR = 3.13; 95%CI (1.86, 5.26)]. It also improved patients’ 1-year [P = 0.03; RD = 0.08; 95%CI (0.01, 0.15)] and 3-year survival rates [P = 0.005; RD = 0.17; 95%CI(0.05, 0.28)]. No significant difference was found for patients’ 5-year survival [P = 0.46; RD = −0.06; 95%CI (−0.21, 0.10)]. Sub-group analysis showed that in patients with positive pre-operative HBV DNA status, HBIG was necessary to reduce HBV recurrence rate [P<0.001; RD = 0.42; 95%CI (0.32, 0.52)]. In patients with negative HBV DNA, combined therapy gained no significant advantages [P = 0.18; RD = 0.06; 95%CI (−0.03, 0.14)]. Non-Lamivudine (non-LAM) antiviral drugs performed as well as combination therapy in prophylaxis of HBV recurrence after LT (P = 0.37; RD = 0.06; 95%CI (−0.02, 0.14)).

Conclusions: HBIG with nucleoside analogues is helpful to reduce HBV recurrence and virus mutants. The necessity of HBIG in prophylaxis of HBV recurrence after LT when using new potent nucleoside analogues, especially for patients with negative pre-transplant HBV DNA status remains to be evaluated.

Introduction

Over 400 million people have been infected with chronic hepatitis B virus (HBV) worldwide, with two-thirds of them in Asia [1]. End-stage HBV related liver diseases, including hepatic cirrhosis, liver failure, and hepatocellular carcinoma, are major indications of liver transplantation (LT) in the above area [2]. However, recipients might suffer from HBV recurrence after LT [3,4,5,6]. In patients without any prophylaxis, HBV recurrence rate can reach as high as 80% [3,4,5]. The application of the first nucleoside analogue, lamivudine (LAM), reduced the recurrence rate of hepatitis B virus after LT dramatically. Unfortunately, its long-term use was associated with the risk of YMDD mutants, which would lead to the failure of hepatitis prevention, and possibly even the loss of the graft and the death of the recipient [7,8,9]. Hepatitis B immunoglobulin (HBIG) is efficient as a passive immune agent against HBV. Long-term passive immunoprophylaxis after LT results in a 60–80% reduction of HBV recurrence [10]. The combination of antiviral drugs and HBIG significantly reduced HBV recurrence rate and YMDD mutants; this strategy is also widely accepted as a routine prophylaxis for HBV recurrence after LT [11,12,13,14].
With the application of new potent nucleoside drugs, some studies have illustrated the effectiveness of nucleosides without HBIG, not only for preventing HBV recurrence but also for controlling YMDD mutants [15,16,17,18,19]. Considering the inconvenience and high cost of long-term HBIG usage as well as the surveillance of hepatitis B surface antibody (HBsAb), the strategy without HBIG would be advantageous if could achieve the same effect. Some analysis have been conducted to compare the efficacy of LAM and HBIG combination therapy with that of LAM monotherapy [11–14], the previous studies have proven the advantages of combined therapy, but the role of HBIG in the era of new nucleosides remains unknown. To gain a better insight into this issue, we performed this meta-analysis to determine the necessity of HBIG in prophylaxis of HBV recurrence after LT. In addition to the observations described by the previous analysis, we also focused on the application of new nucleosides antiviral drugs and of the influence of patients’ pre-transplant HBV DNA status.

**Patients and Methods**

**Search Strategy**

The primary aim of this meta-analysis was to compare the efficacy of antiviral drug therapy with that of antiviral drugs plus HBIG combination therapy after LT. We searched PubMed, Web of Knowledge databases, and Chinese databases including CNKI, Wan Fang and SinoMed until July 2013 to find human studies published. Regardless of language, key words used in the electronic search included ‘liver transplantation’ ‘hepatitis B’ ‘recurrence’ ‘HBIG’ ‘antiviral drugs’. In addition, we reviewed the reference lists of retrieved papers and recent reviews. Hepatitis B recurrence was defined as persistence of HBsAg for 3 weeks, as well as its reappearance in serum after LT.

**Inclusion and Exclusion Criteria**

We set the following inclusion criteria for the studies: (1) Prospective or retrospective cohort studies investigating patients with LT; (2) Studies in which a comparison between antiviral therapy and combination therapy was designated as a primary aim; (3) studies providing sufficient description of the methods; and (4) studies reporting sufficient data on one of the following results: patients’ survival, hepatitis B recurrence rate and YMDD mutants.

The following types of studies were excluded from our analysis: (1) unrelated or in vitro studies; (2) case series, case reports, reviews and conference reports; and (3) studies based on overlapping cohorts from the same institution;

When results from the same center were reported more than once, the newest was extracted. When results from some or all patients in a clinical trial were reported more than once, data on endpoints from the publication with the longest follow-up were extracted.

**Quality Assessment**

A modified Methodological Index for Non-randomized Studies (MINORS) [20] was used to assess the quality of all trials included in this meta-analysis. All of the included trials were assessed for their study aims, patients, data collection, follow-up, groups’ characteristics and statistical analyses.

**Statistical Analysis**

We reviewed all the reported studies. Data were extracted according to clinical and statistical characteristics, duration of follow-up, HBV recurrence, YMDD mutants, and patient survival rate (1 year/3 years/5 years). All of these parameters were analyzed by using the Review Manager Software (version 5.0 for Windows; the Cochrane Collaboration, Oxford, UK), and the results were expressed by risk ratio (RR) or risk difference (RD) with 95% confidence intervals (CI).

**Results**

**Search**

An initial electronic search identified 2899 reports. After the first review, 1782 were excluded for lack of relevance of title or abstract. Among the remaining 1117 articles, 806 were excluded for unrelated trials’ design, and 67 for lacking data on antiviral drugs therapy and antiviral drugs plus HBIG therapy. So, there were 244 reports for more detailed evaluation. After the second review about HBV recurrence, patient survival and YMDD mutant, there were 19 reports determined to be included in the meta-analysis. In total, there are 1484 patients included in this meta-analysis, with 484 in the antivirals therapy group and 1000 in the combination therapy group (Fig. 1).

**Trial Characteristics**

Baseline features of the trials included are shown in Table 1. All the 19 studies included antiviral drugs group and combination therapy group. Study years and follow-ups are not stated in 2 studies. The other 17 had complete follow-up. Patients covered by 17 articles had a follow-up of 6–83 months with different emphases on HBV recurrence, YMDD mutants or patient survival. Of the 19 included studies, 14 administered LAM antivirals therapy in one group and LAM+HBIG combination therapy in the other group. Among the other 5 studies, adefovir dipivoxil (ADV) (10 mg per day) combined with LAM were used in 3, ADV monotherapy was used in 1, and emtricitabine (FTC) (200 mg per day) with tenofovir disoproxil fumarate (TDF) (300 mg per day) in 1. Among these studies, the dosage of LAM is 100 or 150 mg/day and the average dosage of HBIG are 1000 units per month. Quality of included trials was assessed based on the Methodological Index for Non-randomized Studies (MINORS) [20](Table 2).

**HBV recurrence**

HBV recurrence was reported in 18 trials (Fig. 2.A.), and significant differences were observed between the two groups [P < 0.001; RD = 0.16; 95% CI (0.12, 0.20)]. Combination of antiviral drugs and HBIG achieved a more favorable result to reduce the risk of HBV recurrence (Fig. 2.A.). In total, the HBV recurrence rates were 21.1% and 6.2% in antiviral drugs therapy group and combination therapy group respectively.

Subgroup analysis was conducted on patients with clarified pre-operative HBV-DNA status. Among all of the patients, 285 with positive HBV DNA before transplantation were included in 6 trials. It showed that antiviral drug therapy with HBIG was significantly more effective for HBV DNA positive patients [P < 0.001; RD = 0.42; 95% CI (0.32, 0.52)] (Fig. 2.B.). Besides, 4 trials showed that in patients whose HBV DNA were negative before transplantation, there was no significant difference between the two therapies [P = 0.18; RD = 0.06; 95% CI (−0.03, 0.14)] (Fig. 2.C.).

Five trials used non-LAM therapies including ADV, ADV/LAM, and FTC/TDF (Fig. 2.D.). No significant difference was found between non-LAM therapy group and combination therapy group for HBV recurrence [P = 0.17; RD = 0.06; 95% CI (−0.02, 0.14)].

**YMDD mutants**

YMDD mutants were reported in 5 trials (Fig. 3). Significant differences were observed in YMDD mutants rate between
Figure 1. Literature search and selection flow: an overview of the methods used during the literature search.

doi:10.1371/journal.pone.0104480.g001

For more information, visit www.prisma-statement.org.
antiviral drugs therapy group and antiviral drugs combine with HBIG therapy group \([P<0.001; RR = 3.13; 95\% CI (1.86, 5.26)]\). With the use of HBIG, patients showed a lower rate of YMDD mutants rate compared with antiviral drugs therapy.

### Patient survival

One-year, 3-year and 5-year patient survival rate were analyzed (Fig. 4). Six trials calculated the 1-year patients' survival rate in 346 cases. 101 patients in antiviral drugs therapy group showed a 90.1\% 1-year survival rate, and 245 patients in combination therapy group had a 96.3\% 1-year survival rate. 3-year patient survival rates were counted in 4 reports involving 270 patients, which were 71.6\% and 86.7\% for patients in antiviral drugs therapy group and combination therapy group respectively. 111 patients' 5-year survival rates were reported in 3 trials. 82.7\% patients in antiviral drugs therapy group survived longer than 5 years, while in combination therapy group, the 5-year survival rate was 72.9\%.

Combination therapy achieved a higher 1-year and 3-year patient survival rate compared with antiviral therapy group \([1\text{-year survival } P = 0.03; \text{RD} = 0.08; 95\% CI (0.01, 0.15); 3\text{-year survival } P = 0.005; \text{RD} = 0.17; 95\% CI (0.05, 0.28)]\). However, there was no significant difference between the two groups in 5-year patient survival rate \([P = 0.46; \text{RD} = -0.06; 95\% CI (-0.21, 0.10)]\).

### Discussion

Application of nucleoside analogue has reduced the risk of Hepatitis B recurrence after LT dramatically. As the first generation of nucleoside analogue, LAM is safe and well-tolerated with efficacy against hepatitis B. Unfortunately, its long-term use is associated with viral resistance, which will lead to failure of HBV prophylaxis, and even the loss of the grafts and the patients. To reduce the risk of HBV mutating, variant doses of HBIG were introduced and have been very successful. In many transplant centers, prophylaxis with combined LAM and HBIG has been regarded as a routine procedure for such recipients.

The application of HBIG is associated with some disadvantages: inconvenience for patients to receive multiple injections of HBIG and surveillance of antibody titer. Also the cost would be an assignable burden economically. Some efforts have been made to verify the efficiency and safety of prophylaxis without HBIG and have achieved encouraging results \([12,26,28,38]\). Fung J et al have also illustrated that long-term outcome using oral antiviral agents alone without hepatitis B immune globulin is associated with excellent survival \([19]\). While these results were not very convincing due to the lack of well-designed RCT and limitation of sample volumes.

Thus we conducted this meta-analysis to compare antiviral drugs therapy with combined antiviral drugs and HBIG therapy for the prophylaxis of hepatitis B recurrence after LT. We aim to clarify whether it is necessary to use HBIG in liver transplant recipients with HBV related diseases. Compared with previous studies, we also focused on the application of new nucleoside antiviral drugs and patients pre-transplant HBV-DNA status. Since we mainly compared between antiviral drugs therapy with or without long-term combination of HBIG, intro-operative usage of HBIG was not taken into consideration in our comparison.

### Table 1. Characteristics of trials included

| Study                      | Location | Study years | Follow-up (months) | No. patients | Antiviral drugs group/No. patients | Combination therapy group/No. patients |
|----------------------------|----------|-------------|--------------------|--------------|-----------------------------------|--------------------------------------|
| Buti et al. 2007 [21]      | Spain    | 1998–2000   | 83                 | 29           | LAM(n = 20)                       | LAM+HBIG(n = 9)                      |
| Chun-Hui Yuan 2013 [22]    | China    | 2000–2011   | 47.2               | 22           | LAM(n = 6)                        | LAM+HBIG(n = 16)                     |
| Chung Mau Lo 2005 [23]     | Hong Kong, China | 1999–2004 | 21.1               | 16           | LAM/ADV(n = 8)                    | LAM+ADV+HBIG(n = 8)                  |
| Dai J 2009 [24]            | China    | Not mentioned | 69.14              | 55           | LAM(n = 13)                       | LAM+HBIG(n = 42)                     |
| Dean M. Anselmno 2002 [25] | USA      | 1984–2001   | 29                 | 109          | LAM(n = 20)                       | LAM+HBIG(n = 89)                     |
| Dennis A. Freshwater 2008 [12] | UK     | Not mentioned | Not mentioned       | 40           | LAM(n = 10)                       | LAM+HBIG(n = 24)                     |
| Lewis W. Teperman 2013 [26] | USA      | 2007–2011   | 72                 | 37           | FTC/TDF(n = 18)                   | FTC/TDF+HBIG(n = 19)                 |
| Ma Y 2009 [27]             | China    | 2001–2007   | 33.6               | 316          | LAM(n = 106)                      | LAM+HBIG(n = 210)                    |
| Peter W. Angus 2008 [28]   | Australia & New Zealand | 2004–2006 | 21.1               | 34           | ADV/LAM(n = 16)                   | LAM+HBIG(n = 18)                     |
| Shusen Zheng 2006 [29]     | China    | 1999–2004   | 20.13              | 165          | LAM(n = 51)                       | LAM+HBIG(n = 114)                    |
| Xia J 2007 [30]            | China    | 1999–2004   | 44                 | 98           | LAM(n = 40)                       | LAM+HBIG(n = 58)                     |
| Xia N X 2006 [31]          | China    | 2002–2004   | 18                 | 173          | LAM/ADV(n = 5)                    | LAM/ADV+HBIG(n = 168)                |
| Xia Q 2004 [32]            | China    | 2001–2003   | 6                  | 58           | LAM(n = 15)                       | LAM+HBIG(n = 43)                     |
| Yoshida H 2007 [33]        | USA      | 1994–2004   | 67, 54 for two groups | 60          | LAM(n = 26)                       | LAM+HBIG(n = 34)                     |
| Yuan G Y 2002 [34]         | China    | Not mentioned | Not mentioned       | 15           | LAM(n = 13)                       | LAM+HBIG(n = 2)                      |
| Jiao ZY 2007 [35]          | China    | 1999–2005   | 37                 | 84           | LAM(n = 28)                       | LAM+HBIG(n = 56)                     |
| Zhu JP 2003 [36]           | China    | 2000–2001   | 9.3                | 24           | LAM(n = 15)                       | LAM+HBIG(n = 9)                      |
| Schiff 2007 [37]           | Multi-center | 1999–2003 | 7.7                | 57           | ADV(n = 23)                       | ADV+HBIG(n = 34)                     |
| Neff G W 2004 [38]         | USA      | 1994–2003   | 42                 | 92           | LAM(n = 51)                       | LAM+HBIG(n = 41)                     |

*LAM, lamivudine; HBIG, hepatitis B immunoglobulin; ADV: adefovir dipivoxil; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate doi:10.1371/journal.pone.0104480.t001
### Table 2. Quality assessment of included studies.

| Studies                        | End points | Follow-up period | Loss to follow up | control group | Contemporary groups | Baseline of groups | statistical analyses |
|--------------------------------|------------|-----------------|-------------------|---------------|---------------------|--------------------|---------------------|
| Buti et al. [21]               | A          | A               | A                 | A             | A                   | A                  | A                   |
| Chun-Hui Yuan et al. [22]      | A          | A               | A                 | A             | A                   | A                  | A                   |
| Chung Mau Lo et al. [23]       | A          | A               | A                 | A             | A                   | B                  | A                   |
| Dai J et al. [24]              | A          | A               | A                 | A             | C                   | A                  | A                   |
| Dean M. Anselmo et al. [25]    | A          | A               | A                 | A             | C                   | A                  | A                   |
| Dennis A Freshwater et al. [12] | A          | B               | A                 | A             | A                   | A                  | A                   |
| Lewis W. Teperman et al. [26]  | A          | A               | A                 | A             | A                   | A                  | A                   |
| Ma Y et al. [27]               | A          | A               | A                 | A             | C                   | A                  | A                   |
| Peter W. Angus et al. [28]     | A          | A               | A                 | A             | A                   | A                  | A                   |
| Shusen Zheng et al. [29]       | A          | A               | A                 | A             | A                   | B                  | A                   |
| Xia J et al. [30]              | A          | A               | A                 | A             | A                   | C                  | A                   |
| Xia N X et al. [31]            | A          | A               | A                 | A             | A                   | B                  | A                   |
| Xia Q et al. [32]              | A          | A               | A                 | A             | A                   | B                  | A                   |
| Yoshida H et al. [33]          | A          | A               | A                 | A             | A                   | A                  | A                   |
| Yuan G et al. [34]             | A          | B               | A                 | A             | A                   | B                  | A                   |
| Jiao ZY et al. [35]            | A          | A               | A                 | A             | A                   | A                  | A                   |
| Zhu JP et al. [36]             | A          | A               | A                 | A             | A                   | A                  | A                   |
| Schiff et al. [37]             | A          | A               | A                 | A             | A                   | A                  | A                   |
| Neff G W et al. [38]           | A          | A               | A                 | A             | C                   | A                  | A                   |

(1) End points: A, Endpoints appropriate to the aim of the study; B, no description about endpoints; C, endpoints inappropriate to the aim of the study. (2) Follow-up period: A, follow-up appropriate to the aim of the study; B, follow-up was not mentioned; C, follow-up in inappropriate to the aim of the study. (3) Loss to follow-up: A, loss to follow-up less than 5%; B, no description about the loss; C, loss to follow-up over than 5%. (4) Control group: A, an adequate control group; B, no description about control group; (5) Contemporary groups: A, control and studied groups were managed during the same time period; B, no description about the time period of groups; C, control and studied groups were historical comparison. (6) Baseline of groups: A, groups were similar regarding the criteria other than the studied endpoints (like age, sex); B, no description about the baselines; C, baseline unequal among groups. (7) Statistical analyses: A, adequate statistical analyses; B, inadequate statistical analyses.
Figure 2. Antiviral drugs or antiviral drugs combined with HBIG in prophylaxis of hepatitis B recurrence after liver transplantation: results of a meta-analysis: HBV recurrence rate. (Columns represent the risk difference of each study. Diamonds represent the overall effect size, and diamond widths represent the overall 95% confidence interval.)

doi:10.1371/journal.pone.0104480.g002
Antiviral drugs therapy following a period of combination therapy was also regarded as a monotherapy strategy [20,23,25,29]. As shown in this meta-analysis, combination therapy has a significant advantage in terms of HBV recurrence and the virus mutation. It can also improve the 1 year and 3 year survival of the patients, although no significant improvement in patients’ long-term survival has been observed.

Patients’ pre-transplant virus replication status has been documented as the most important risk factor for virus recurrence and virus mutation; HBV DNA has always been regarded as a

| Study or Subgroup             | Events | Total | Events | Total | Weight | Risk Ratio | M-H, Fixed, 95% CI |
|-------------------------------|--------|-------|--------|-------|--------|------------|-------------------|
|                               | Antivirals | Antivirals + HBIG | Risk Ratio | M-H, Fixed, 95% CI |
| Dennis A. Freshwater 2008     | 3       | 10    | 1      | 24    | 4.4%   | 7.20 [0.85, 61.17] |
| Jiao 2007                     | 4       | 28    | 2      | 56    | 9.9%   | 4.00 [0.78, 20.53] |
| Ma Y 2009                     | 9       | 106   | 5      | 210   | 24.9%  | 3.57 [1.23, 10.38] |
| Maria Buti 2007               | 2       | 20    | 1      | 9     | 10.3%  | 0.90 [0.09, 8.69]  |
| Shusen Zheng 2006             | 14      | 51    | 11     | 114   | 50.5%  | 2.84 [1.39, 5.83]  |
| Total (95% CI)                | 215     | 413   | 100.0% | 3.13 [1.86, 5.26] |
| Total events                  | 32      | 20    |        |       |        |             |

Heterogeneity: Chi² = 1.95, df = 4 (P = 0.74); I² = 0%
Test for overall effect: Z = 4.31 (P < 0.0001)

Figure 3. Antiviral drugs or antiviral drugs combined with HBIG in prophylaxis of hepatitis B recurrence after liver transplantation: results of a meta-analysis: YMDD mutants. (Columns represent the risk ratio of each study. Diamonds represent the overall effect size, and diamond widths represent the overall 95% confidence interval.) doi:10.1371/journal.pone.0104480.g003

| Study or Subgroup             | Events | Total | Events | Total | Weight | Risk Difference (Non-event) | M-H, Fixed, 95% CI |
|-------------------------------|--------|-------|--------|-------|--------|----------------------------|-------------------|
|                               | Antivirals | Antivirals + HBIG | Risk Difference (Non-event) | M-H, Fixed, 95% CI |
| Chun-Hui Yuan 2013            | 6       | 6     | 16     | 16    | 6.4%   | 0.00 [-0.21, 0.21]         |
| Chung Mau Lo 2006             | 8       | 8     | 7      | 8     | 5.9%   | -0.13 [-0.41, 0.16]        |
| Dai J 2009                    | 13      | 13    | 42     | 42    | 14.6%  | 0.23 [0.00, 0.48]          |
| Dean M. Anselmo 2002          | 15      | 20    | 83     | 89    | 24.0%  | 0.18 [-0.01, 0.38]         |
| Jiao 2007                     | 27      | 28    | 55     | 56    | 27.4%  | 0.02 [-0.06, 0.09]         |
| Yoshida H 2007                | 25      | 26    | 33     | 34    | 21.7%  | 0.01 [-0.08, 0.10]         |
| Subtotal (95% CI)             | 101     | 245   | 100.0% | 0.08 [0.01, 0.15] |
| Total events                  | 91      | 236   |        |       |        |             |

Heterogeneity: Chi² = 9.60, df = 5 (P = 0.09); I² = 48%
Test for overall effect: Z = 2.15 (P = 0.03)

Figure 4. Antiviral drugs or antiviral drugs combined with HBIG in prophylaxis of hepatitis B recurrence after liver transplantation: results of a meta-analysis: 1-year/3-year/5-year patient survival rate. (Columns represent the risk difference of each study. Diamonds represent the overall effect size, and diamond widths represent the overall 95% confidence interval.) doi:10.1371/journal.pone.0104480.g004
representative for HBV replication status [29,35,36]. In patients with negative pre-transplant HBV DNA, the risk of virus recurrence is much lower [35,36]. Neff [36] reported that no additional advantage was conferred by combined use of LAM and HBIG compared with LAM monotherapy in patients with negative pre-transplant HBV DNA. In his study, 33 and 18 additional advantage was conferred by combined use of LAM and combination therapy groups respectively. Combination therapy significantly reduced the HBV recurrence rate for those with positive HBV DNA before LT [P = 0.17; RD = 0.06; 95% CI (0.32, 0.52)], but due to lack of patients' HBV-DNA status before the operation. Well-designed RCTs with large samples are still needed to evaluate the necessity of HBIG after LT.

New nucleotide analogues including ADV and TDF have been proven effective and superior to LAM without risk of viral mutation [26,28,37,40]. Some trials have also proven that maintenance therapy with newer nucleoside analogues after discontinuation of HBIG prophylaxis was effective [16,41]. Based on their findings, we assumed that HBIG might be unnecessary during the post-transplantation period when the new analogues were used, and we performed a sub-group analysis of non-LAM antiviral versus combination therapy. As showed in our sub-group analysis, when using the new nucleoside analogues, there is no significant difference between the two groups for hepatitis B recurrence [P = 0.17; RD = 0.06; 95% CI (0.32, 0.52)], but due to lack of patients' HBV-DNA status before LT and limited number of samples, this result is not compelling and remains to be determined. Patients' survival analysis showed that use of HBIG is beneficial in terms of 1-year and 3-year survival. And surprisingly, it showed no significant advantages for 5-year survival. Limited studies and small sample size might be an important reason for this result, in our analysis, only 3 studies evaluated 5-year survival rate, and there were only 111 patients in total.

There are several limitations to our study. Firstly, since LAM has been studied before, we had planned to evaluate the role of HBIG in such an era that new nucleoside drugs are used, while after an extensive literature searching, 14 of 19 included articles were about the use of LAM, among the other 5 studies adopted non-LAM antiviral drugs, ADV combined with LAM were used in 3, ADV monotherapy was used in 1, and FTC with TDF in 1 [22,25,27,30,36]. We included all of these researches and hopefully to get a convincing result on the basis of a large sample. Secondly, most of the included trials were not RCTs and 8 studies were retrospective studies. Thirdly, a few of included studies didn't set strict antiviral drugs therapy groups. For example, in Teperman's studies [25], they used a period of combination therapy before a comparison of antiviral drugs group with combination therapy. Aiming to evaluate the efficacy of HBIG in the long term prognosis after LT, we didn’t exclude these literatures. The fourth limitation of our study is the lack of conditions of patients' pre-transplant HBV DNA. Nevertheless, we were able to draw a more convincing conclusion that the use of HBIG could be linked with patients' pre-transplant HBV DNA conditions.

In summary, this meta-analysis has found that HBIG is useful for prophylaxis of hepatitis B recurrence and YMDD mutants, but there is no significant difference between the antiviral drug therapy and combination of HBIG therapy with regard to patients' long-term survival. With the application of new nucleoside analogues, HBIG may be not necessary, especially in patients with negative HBV-DNA status before the operation. Well-designed RCTs with larger samples are still needed to evaluate the necessity of HBIG after LT.

### Supporting Information

**Checklist S1** PRISMA Checklist. (DOC)

**Author Contributions**
Conceived and designed the experiments: PW LW XH. Analyzed the data: PW NT HW. Wrote the paper: PW NT HW HZ PC LW.

### References

1. Lai CL, Ratziu V, Yuen MF, Poynard T (2003) Viral hepatitis B. Lancet 362: 2089–2094.
2. Popescu I, Ionescu M, Brasoveanca V, Hrehoret D, Matei E, et al. (2010) [Liver transplantation—indications, surgical technique, results—the analysis of a clinical series of 200 cases]. Chirurgia (Bucur) 105: 177–186.
3. Freeman RB, Sanchez H, Lewis WD, Sherburne B, Dzik WH, et al. (1991) Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 51: 793–797.
4. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, et al. (1992) Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 14: 104–111.
5. Samuel D (2005) The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 37 suppl 2: S183–S189.
6. Starzl TE, Demetris AJ, Van Thiel D (1989) Liver transplantation (1). N Engl J Med 321: 1014–1022.
7. Lo CM, Fan ST, Liu CL, Lai CL, Wong J (2003) Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 75: 581–584.
8. Saab S, Kim M, Wright TL, Han SH, Martin P, et al. (2000) Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 119: 1382–1384.
9. Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, et al. (2008) [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients]. Nan Fang Yi Ke Da Xue Xue Bao 28: 1010–1012.
10. Honaker MR, Showuchi-Amni MH, Vera SR, Alloway RR, Grewal HP, et al. (2002) Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transplant Inf Dis 4: 137–143.
11. Brock GN, Mostapraf F, Ferguson N, Carrubba CJ, Eng M, et al. (2011) Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int 24: 570–571.
12. Freshwater DA, Duffy T, Cane P, Motimer DJ (2008) Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 85: 1105–1111.
13. Kao W, Wu X, Xiao D (2009) Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 22: 387–394.
14. Yamamoto M, Little G, Imagawa DK (2009) Hepatitis B immunoglobulin in preventing reinfection following liver transplantation. Expert Rev Anti Infect Ther 7: 321–328.
15. Fung J, Chuang C, Chan SC, Yuen MF, Chok KS, et al. (2011) Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 141: 1212–1219.
28. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E (2008) A
depression of hepatitis B e antigen and HBV-DNA following anti-HBc
hepatitis B virus infection. Lancet 371: 551–553.

27. Yi MA, Qiang T, Xiao-shun HE, Guo-dong W, An-bin HU (2009) Prevention
and treatment of hepatitis B virus infection. CHINESE JOURNAL OF DIGESTIVE SURGERY 47: 1209–1212.

26. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, et al. (2013)
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin
after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 58: 67–73.

19. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, et al. (2013) Oral
nucleoside/nucleotide analogs without hepatitis B immune globulin after liver
transplantation for hepatitis B. Am J Gastroenterol 108: 942–948.

18. Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, et al. (2013)
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis
B immunoglobulin withdrawal after liver transplantation. Liver Transpl 19:
594–601.

17. Perrillo R (1999) Multicenter studies of Lamivudine for the treatment and
prevention of hepatitis B after liver transplantation. Ochsner J 1: 33–36.

16. Grellier L, Mutimer D, Ahmed M, Brown D, Burrells AK, et al. (1996)
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis
B cirrhosis. Lancet 348: 1212–1215.

15. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, et al. (2007) Adherence to
nucleoside/nucleotide analogs and hepatitis B e antigen at 5 years after liver
transplantation. Hepatology 45: 106–109.

14. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, et al.
(2003) Methodological index for non-randomized studies (minors): development and
validation of a new instrument. ANZ J Surg 73: 712–716.

13. Zheng S, Chen Y, Liang T, Lu A, Wang W, et al. (2006) Prevention of hepatitis
B recurrence after liver transplantation using lamivudine or lamivudine
combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 12:
253–258.

12. Yi MA, Qiang T, Xiao-shun HE, Guo-dong W, An-bin HU (2009) Prevention
and treatment of HBV reinfection after liver transplantation. CHINESE JOURNAL OF DIGESTIVE SURGERY 6: 348–351.

11. Xia N, Fu Z, Qiu B, Wang Z, Li X, et al. (2006) [Low-dose intra-muscular
hepatitis B immunoglobulin combined with lamivudine for long-term prophylax-
is of hepatitis B recurrence after liver transplantation]. WORLD CHINESE JOURNAL OF DIGESTOLOGY 14: 1288–1293.

10. Yuan CH, Xiu DR, Jiang B, Li ZF, Li L, et al. (2013) HBV recurrence lowered
by lamivudine/HBIG combination therapy in liver transplant patients: ten-year
experience. Hepatobiliary Pancreat Dis Int 12: 149–153.

9. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, et al. (2005) Liver transplantation
for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on
adefovir dipivoxil plus lamivudine. Liver Transpl 11: 807–813.

8. Ticciati LM, Ghebrial RM, Jung LC, Weaver M, Cao C, et al. (2002) New era of
liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 235:
611–619, 619–620.

7. Yi MA, Qiang T, Xiao-shun HE, Guo-dong W, An-bin HU (2009) Prevention
and management of hepatitis B virus reinfection after liver transplantation.
CHINESE JOURNAL OF ORGAN TRANSPLANTATION 25: 53.

6. Zhu JP, Zhang TL, Li Y, Yuan J, Song SB, et al. (2003) Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary
Pancreat Dis Int 2: 500–503.

5. Neff GW, O’Brien CB, Nery J, Shire N, Montalbano M, et al. (2004) Outcomes
during liver transplant recipients with hepatitis B virus infection. Clin Transplant 21:
166–171.

4. Yuan G, Duan Y, Wang F, Liang SS, Zhu L, et al. (2002) [Prevention and treatment of HBV reinfection following liver transplantation]. Zhonghua Gan Zang Bing Za Zhi 10: 14–16.

3. Jiao ZY, Jia ZJ, Fung JY, Lo CM (2013) Prevention of recurrent hepatitis B infection
by lamivudine/HBIG combination therapy in liver transplant patients: ten-year
experience. Hepatobiliary Pancreat Dis Int 12: 465–472.

2. Schaff E, Lai CL, Hadziyannis S, Neuaus P, Terrault N, et al. (2007) Adefovir
dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-
resistant hepatitis B: final long-term results. Liver Transpl 13: 349–360.

1. Jie X, Zhan-yu Y, Jia C, Rui L, Nan Z, et al. (2007) [Prevention and treatment of hepatitis B virus infection]. CHINESE JOURNAL OF ORGAN TRANSPLANTATION 15: 106–109.

Hepatitis B Immunoglobulin after Liver Transplantation